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Abstract
The potential role of calcimimetics as vasculotropic agents has been suggested since the
discovery that calcium sensing receptors (CaSRs) are expressed in cardiovascular tissues.
However, whether this effect is CaSR-dependent or -independent is still unclear. In the pres-
ent study the vascular activity of calcimimetic R-568 was investigated in mesenteric vascular
beds (MVBs) isolated from Spontaneously Hypertensive rats (SHR) and the relative age-
matched Wistar-Kyoto (WKY) control rats. Pre-constricted MBVs were perfused with
increasing concentrations of R-568 (10 nM– 30 μM) resulting in a rapid dose-dependent
vasodilatation. However, in MVBs from SHR this was preceded by a small but significant
vasoconstriction at lowest nanomolar concentrations used (10–300 nM). Pre-treatment with
pharmacological inhibitors of nitric oxide (NO) synthase (NOS, L-NAME), KCa channels
(CTX), cyclo-oxygenase (INDO) and CaSR (Calhex) or the endothelium removal suggest
that NO, CaSR and the endothelium itself contribute to the R-568 vasodilatory/vasoconstric-
tor effects observed respectively in WKY/SHR MVBs. Conversely, the vasodilatory effects
resulted by highest R-568 concentration were independent of these factors. Then, the ability
of lower R-568 doses (0.1–1 μM) to activate endothelial-NOS (eNOS) pathway in MVBs
homogenates was evaluated. The Akt and eNOS phosphorylation levels resulted increased
in WKY homogenates and Calhex significantly blocked this effect. Notably, this did not
occur in the SHR. Similarly, vascular smooth muscle cells (vSMCs) stimulation with lower
R-568 doses resulted in Akt activation and increased NO production in WKY but not in SHR
cells. Interestingly, in these cells this was associated with the absence of the biologically
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active dimeric form of the CaSR thus potentially contributing to explain the impaired vasore-
laxant effect observed in response to R-568 in MVB from SHR compared to WKY. Overall,
these findings provide new insight on the mechanisms of action of the calcimimetic R-568 in
modulating vascular tone both in physiological and pathological conditions such as
hypertension.
Introduction
The extracellular calcium (Ca2+) sensing receptors (CaSRs) are important in maintaining and
regulating mineral ion homeostasis in parathyroid, kidney, gut and bone tissues [1, 2]. The dis-
covery that CaSRs are widely expressed in the heart as well as in the blood vessels has suggested
their physiological involvement in cardiovascular processes such as vessel remodeling and cal-
cification; similarly, acute CaSR-mediated activation has been proposed to participate in the
maintenance of vascular tone and modulation of blood pressure levels [3–8]. However,
whether the aforementioned cardiovascular effects are secondary to CaSR-dependent regula-
tion of Ca2+ homeostasis in other organs or directly related to CaSR modulation in vascular tis-
sues is still unclear, and the exact mechanisms underlying CaSR activation remain to be
elucidated [3].
In the local control of vascular tone, the role played by the endothelial-mediated release of
the vasodilator nitric oxide (NO) is universally recognized [9]. A direct vascular function of
the endothelial CaSR is supported by the finding that stimulation of human aortic endothelial
cells with polyamine spermine (CaSR type I agonist) leads to an increase of intracellular Ca2+
accompained by NO production [10], whereas treatment with the CaSR antagonist NPS2390
attenuates extracellular Ca2+-dependent NO-mediated relaxation in endothelium-intact aortic
rings from mice [11].
Interestingly, CaSR seems also actively involved in the modulation of myogenic tone in
response to changes in Ca2+ concentration, as initially demonstrated in rat subcutaneous small
arteries and more recently observed in aorta and mesenteric artery of transgenic mice with
specific CaSR knockout (CaSR KO) in vascular smooth muscle cells (vSMCs) [5, 12]. These
data, together with other recent evidences, suggest that CaSR may mediate a dual direct activity
on blood vessels: activation of endothelial CaSR results in a NO-dependent pro-relaxing effect,
whereas stimulation of CaSR located on vSMCs may elicit a pro-contractile effect [13, 14].
Based on these observations, the development and investigation of compounds able to
modulate CaSR activity might represent an additional strategy in the control of cardiovascular
homeostasis. Nevertheless, in vitro and ex vivo studies on vSMCs and endothelial cells suggest
that drugs proposed as calcimimetics might be able to regulate vascular tone independently
from CaSR activation [15–18]. For example, a CaSR-independent relaxant effect of calcimi-
metics has been ascribed to their ability to inhibit the Ca2+ influx via L-type Ca2+ channels [15,
16]. Other authors have proposed that calcimimetic-mediated NO production might depend
on stimulation of the big or large conductance Ca2+-activated potassium channel (BKCa)
channels in vSMCs [18], while activation of intermediate conductance Ca2+-activated potas-
sium (IKCa) channels in endothelium may explain vasorelaxation through release of endothe-
lium-derived hyperpolarizing factor (EDHF) [19, 20].
These observations are in line with our recent findings [17], evaluating the activity of calci-
mimetic R-568, a type II indirect allosteric CaSR modulator [21], in human umbilical vein
endothelial cells (HUVECs). We found that, although expressed in endothelial cells, CaSR
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protein was mainly distributed in cytoplasm, while the functional CaSR dimers usually localize
on the plasma membrane. In addition, increased intracellular Ca2+ concentration and endo-
thelial NO synthase (eNOS) activation in response to both R-568 and its enantiomer S-568
were unchanged in the absence or the presence of the CaSR blocker Calhex-231 [17]. Accord-
ingly, an acute and CaSR-independent hypotensive effects has been reported following infu-
sion of R-568 and S-568 in rat renal and mesenteric arteries [22]. Therefore, whether R-568
may exert CaSR-dependent or CaSR-independent vascular effects that might physiologically
contribute to regulation of vascular tone is still under debate.
Finally, to add complexity, it is important to consider that calcimimetic-dependent vascular
effects might vary under conditions altering endothelial function/integrity such as hyperten-
sion. On this regard results are still controversial, since some studies report an in vivo calcimi-
metic hypotensive effects in both normotensive [23] and spontaneously hypertensive (SHR)
rats [24] while others found that R-568 significantly decreased blood pressure in uremic and
SHR animals, but not in normotensive rats [25]. Importantly, when these drugs are adminis-
tered in vivo, the hypothetical contribution of direct vascular effects and the calcimimetic-
mediated suppression of parathyroid hypertensive factors are hard to dissect [3].
This last observation suggests that studies on isolated and perfused vessels might offer the
possibility to evaluate the direct vascular effects of calcimimetics avoiding confounding factors
such as modulation of calcium in non-cardiovascular districts. In the present study, the poten-
tial CaSR-dependent/independent vasodilatory effects of R-568, along with the intracellular
signaling pathway activated, was comparatively evaluated in mesenteric vascular bed (MVB)
and cultured vSMCs, from SHR rats and normotensive WKY controls.
Materials and methods
Animals
All procedures in animals were performed in accordance with the Guide for the Care and Use
of Laboratory Animals (NIH Publication No. 85–23, revised 1996) and approved by the Com-
mittee on the Ethics of Animal Experiments of the University of Bari (Prot. N. 60901-X/10)
under Authorization for the Use of Laboratory Animals (Italian Government, Ministry of
Health, Prot. N.86851493).
Twenty 8-week old male Spontaneously Hypertensive rats (SHR, 311.0 ± 7.14 g) and twenty
age-matched normotensive Wistar-Kyoto (WKY, 309.5 ± 9.7 g) control rats were obtained
from Charles River (Milan, Italy) and used in all studies. Animals were housed in 12 hours
light/dark cycle, at 22˚C, and allowed ad libitum access to diet and water.
The blood pressure of WKY and SHR rats was randomly measured in conscious rats using
BP-2000 (Visitech Systems, Apex, North Carolina, USA), a non-invasive computerized system
for recording blood pressure from rodent tails. Systolic blood pressure, measured at 8 weeks,
ranged from 119 to 137 mmHg in WKY and from 153 to 176 mmHg in SHR.
Rats were anesthetized with sodium pentobarbital (80 mg/kg body weight i.p.), heparinized
(400 U.I./100g body weight i.p.) and euthanized by cervical dislocation. All efforts were made
to minimize animal suffering.
Reagents
Heparin was purchased from Pfizer (Pfizer Srl, Rome, Italy); noradrenaline (NA), acetylcho-
line (ACh), Nω-nitro-L arginine methyl ester (L-NAME), charybdotoxin (CTX) and indo-
methacin (INDO) were purchased from Sigma (Sigma-Aldrich Chemicals, St.Louis, MO,
USA). Stock solutions of NA (100 mM) and ACh (10 mM) were prepared with distilled water.
R-568 hydrochloride powder was provided by Amgen (Amgen, Inc., Thousand Oaks, CA,
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USA), resuspended in distilled water at 2 mM concentration and stored at -20˚C. Calhex-231
(Santa Cruz Biotechnology, Heidelberg, Germany) was resuspended in ethanol at 10 mM con-
centration and stored at -20˚C. Final dilutions of all drugs were prepared in modified Krebs-
Henseleit solution immediately before use.
Ex-vivo vascular studies
Mesenteric vascular beds (MVB) were isolated and removed from fourteen WKY and fourteen
SHR rats as previously described [26]. Briefly, MVB mounted in a temperature-controlled
moist chamber (type 834/1, Hugo Sachs Elektronik, March-Hungstetten, Germany) were per-
fused with modified Krebs-Henseleit solution continuously gassed with a mixture of 95% O2
and 5% CO2 (pH 7.4). A constant flow rate of 5 ml/min through the MVB was maintained
using a peristaltic pump (ISM 833; Hugo Sachs Elektronik, March-Hungstetten, Germany).
Drug solutions were infused into the perfusate proximal to the arterial cannula using another
peristaltic pump. After an equilibration period (30–40 min), changes in perfusion pressure
(PP) were measured with a Pressure Transducer System (SP 844 Capto, Horten, Norway) and
recorded continuously using data acquisition and analysis equipment (PowerLab System,
ADInstruments, Castle Hill, Australia).
Vasodilator responses in MVB were measured in vessels pre-constricted with NA according
to previous studies [27], to obtain comparable baseline PP values of approximately 120 mmHg
in WKY and SHR, MVB preparations were continuously perfused with NA 10 and 3 μM,
respectively. Dose-response curves measuring vasodilation (decrease in PP) in response to R-
568 were obtained by adding increasing concentrations of R-568 (10 nM– 30 μM/4 min perfu-
sion) into the perfusate. Relative changes in PP at steady-state reached with each dose were
measured and expressed in mmHg. For all vasodilation experiments, data from each curve
were then normalized to PP obtained with a maximally stimulating dose of ACh (1 μM, 100%
representing initial steady-state perfusion pressure and 0% representing maximal reduction in
response to ACh). In some experiments, R-568-induced relaxation was measured after 20-min
treatment with NOS inhibitor L-NAME (100 μM), alone or combined with large and interme-
diate-conductance Ca2+-activated potassium channels (BKCa and IKCa) antagonist CTX (300
nM) and cyclooxygenase 1/2 (COX1/2) inhibitor INDO (10 μM). In other experiments, R-
568-induced relaxation was measured in the absence and in the presence of CaSR blocker Cal-
hex-231 (3 μM), or in the absence of endothelium. Endothelium removal was performed by
flushing vessels intermittently with air for several minutes as previously described [27] and
verified by complete lack of vasodilation induced by infusion of 1 μM ACh.
Cell cultures
Vascular smooth muscle cells (vSMCs) were obtained from thoracic aortas of six normotensive
(WKY-vSMCs) and six hypertensive (SHR-vSMCs) animals as previously described [28–30].
Briefly, thoracic aortas were dissected, transferred into a Petri dish containing Dulbecco’s
Modified Eagle’s Medium low glucose (DMEM-LG) and discharged from fatty tissues. Subse-
quently, aortas were cut longitudinally and endothelial cells were removed through rubbing.
The three vessel layers were cut into small pieces (1–2 mm) and maintained for 2 hours at
37˚C in DMEM-LG containing 0.1% elastase and 0.1% collagenase type IA. Following a centri-
fugation to 250 g for 10 min, the supernatant were discarded and the cells were re-suspended
in culture medium composed of Ham’s F12 Medium (Sigma-Aldrich Chemicals, St.Louis,
MO, USA), 20% Fetal Bovine Serum (FBS, Gibco-Life Technologies, Monza, Italy), 1% penicil-
lin/streptomycin and 1% L-glutamine (Sigma-Aldrich Chemicals, St.Louis, MO, USA). The
cells were growth under a controlled atmosphere (5% CO2 and 37˚C) until confluence (8 ± 10
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days). The characterization of α- smooth muscle actin (α-SMA) expression in WKY/SHR-
vSMCs was performed by flow cytometry.
In all experiments, vSMCs were starved for 16 hours with Ham’s F12 Medium (Sigma-
Aldrich Chemicals, St.Louis, MO, USA) containing 0.1% Fetal Bovine Serum (FBS, Gibco-Life
Technologies, Monza, Italy), and subsequently stimulated with R-568 molecule (1 μM). In
some experiments, before stimulation with R-568, cells were pre-incubated for 15 minutes
with CaSR Inhibitor, Calhex 231 (1 μM).
Flow cytometry
The protein expression of α-SMA in permeabilized WKY- and SHR- vSMCs was evaluated by
fluorescent-activated cell sorting (FACS) FACS Canto II (BD Bioscences, California, USA).
Briefly, WKY- and SHR- vSMCs were pelleted by centrifugation at 1500 rpm for 5 min and
resuspended in PBS. Then, 5×105 cells/sample were fixed and permeabilized using FACS Lys-
ing and Permeabilizing Solution (BD, CAT. 349202 and 340973 respectively). Permeabilized
cells were incubated with a mouse monoclonal against α-SMA (Sigma-Aldrich, 1:100) for 30
minutes on ice and successively stained with the corresponding secondary antibody (Anti-
mouse FITC, 1:100, Jackson ImmunoResearch) for 30 min on ice. To assess non-specific fluo-
rescence, samples were stained with the secondary antibody alone (control).
NOS activity
NOS activity was evaluated in the WKY and SHR cells by measuring the conversion of L-
[3H]-arginine into L-[3H]-citrulline as previously described [28, 31]. Briefly, WKY- and SHR-
vSMCs were grown at confluence and then stimulated with R-568 (1 μM) in the absence or the
presence of Calhex-231(1 μM). Subsequently, cells were detached, resuspended in 0.2 ml of
reaction buffer (20 mmol/L Hepes-Na+, 0.5 mmol/L EDTA, 1 mmol/L dithiothreitol, pH 7.2)
and sonicated on ice. In each test tube containing 100 μl of cell lysate, the following reagents
were added: 2 mmol/L NADPH, 1.5 mmol/L CaCl2, 0.1 mmol/L tetrahydrobiopterin (BH4,
Sigma-Aldrich Chemicals, St.Louis, MO, USA), 2.5 μCi L-[3H]-arginine (corresponding to
0.4 μM) (Perkin Elmer SpA, Milan, Italy). After 15 min incubation at 37˚C, the reaction was
stopped by adding 2 ml Hepes-Na+ pH 6 containing 2 mmol/L EDTA; the entire reaction mix-
ture was applied to 2 ml of Dowex AGWX8-200 columns (Sigma-Aldrich Chemicals, St.Louis,
MO, USA) and eluted with 4 ml of water. The radioactivity corresponding to L-[3H]-citrulline
content in the eluate was measured by a liquid scintillation analyzer (Perkin Elmer SpA,
Milan, Italy). NOS activity was expressed as pmol/NO/min/mg protein total.
Immunoblotting analysis
Expression of protein of interest in vSMCs and whole vessel lysates was assessed by immuno-
blotting with specific antibodies according to standard methods [32]. In each sample, total
protein content was quantified using the BCA Protein Assay Kit (Pierce Biotechnology Inc,
Rockford, USA). Samples were subjected to electrophoretic separation by 8–10% SDS-PAGE.
For tissue samples, MVB homogenates (35 μg) were immunoblotted with α-eNOS (BD Trans-
duction Laboratories, CA, USA), phospho-eNOSSer1179, Akt, phospho-AktSer473 (Cell Signaling
Technology, Leiden, Netherlands), or monoclonal anti-α smooth muscle actin (α-actin,
Sigma-Aldrich Chemicals, St.Louis, MO, USA) antibodies (1:1000, at 4˚ C overnight). For
vSMCs, lysates (30 μg) were immunoblotted with CaSR (Thermo Fisher Scientific, Milan,
Italy) and its positive (HEK293 CaSR transiently transfected cell lysate) and negative (HEK293
empty vector transfected control cell lysate) controls (both from Novus Biologicals, UK), Akt,
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phospho-AktSer473 and β-actin (Sigma-Aldrich Chemicals, St.Louis, MO, USA) antibodies
(1:1000, at 4˚ C overnight).
Incubation with specific mouse or rabbit HRP-linked secondary antibodies (1:3000; Santa
Cruz Biotechnology, Heidelberg, Germany) was performed for 1 h at room temperature.
Immunoblotting results were visualized using enhanced chemiluminescence (ECL) reagents
(Amersham Pharmacia Biotech SpA, Milan, Italy) by Molecular Imager1 ChemiDocTM XRS
System (Bio-Rad Laboratories Srl, Milan, Italy). Images were captured with QuantityOne Soft-
ware (Bio-Rad Laboratories Srl, Milan, Italy) and blots quantified by scanning densitometry
(ImageJ, NIH, Bethesda). In some experiments, the immunoreactive bands were detected
using the Alliance 4.7 system (Uvitec Limited, Cambridge, UK).
Statistical analysis
Results were expressed as mean ± SEM of n experiments (n = number of rats) for ex-vivo
experiments, while in-vitro results were expressed as mean ± SD. Two-way ANOVA for
repeated measures and Student’s t tests (paired or unpaired) were used as appropriate. Values
of p< 0.05 were considered to indicate statistical significance.
Results and discussion
Vascular effects of R-568 in MVB from WKY and SHR rats
Calcimimetics are allosteric CaSR activators proposed as potential anti-hypertensive drugs fol-
lowing the discovery that their systemic administration reduces blood pressure in animal mod-
els [3–5]. However, although CaSRs are expressed on endothelial and vSMC cells, their role in
the regulation of vascular tone under healthy and pathophysiological conditions has not been
definitively clarified [33]. Moreover, both CaSR-dependent and CaSR–independent mecha-
nisms have been proposed to explain calcimimetic hemodynamic effects with uncertain and
sometimes controversial results [5, 10, 12, 15–18].
To shed light on these issues, we investigated cellular mediators and signaling mechanisms
responsible for the direct vascular effects of the calcimimetic R-568 on whole perfused vessels
and on isolated vSMCs obtained from spontaneously hypertensive rats (SHR) and their rela-
tive Wistar-Kyoto (WKY) controls. SHR animals share many common features with human
genetic hypertension and, at 8-week of age, they manifest endothelial dysfunction and are
prone to vascular dysreactivity [34]. Importantly, changes in endothelial function observed in
mesenteric vascular bed (MVB) have been shown to parallel, or even precede, changes in vas-
cular reactivity, elasticity, and volume of large conductance arteries [27]; therefore, the behav-
iour of this vascular district is considered a useful proxy for the function of vascular beds that
contribute more directly to systemic blood pressure [27, 33].
MVB from SHR rats are significantly more sensitive and responsive to the vasoconstrictor
actions of NA with respect to MVB from WKY [27]. Based on this, and according to previous
experience [26, 27, 35, 36] we infused NA at 3 μM or 10 μM concentration, respectively, to
obtain a similar baseline perfusion pressure (PP) of ~120 mmHg, rather than infusing an iden-
tical NA dose for both SHR and WKY. The NA concentration chosen was the dose achieving
submaximal vasoconstriction in SHR and WKY, respectively, from dose-response curves (10
nm—10 μM) preliminary obtained ex-vivo. Before administration of R-568, a supramaximal
dose of the vasodilator ACh (1 μM) was added to verify endothelial integrity. Subsequently,
increasing concentrations of R-568 (10 nM– 30 μM/4 min perfusion) were infused in a non-
cumulative manner into the preparations.
As shown in Fig 1A, administration of R-568 in MVB from WKY resulted in a rapid,
reversible, and dose-dependent reduction of PP, starting with the lowest concentration used
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Fig 1. Vascular effects of R-568 in MVB from WKY and SHR rats. Mesenteric vascular beds (MVB) from 8-week
old WKY and SHR rats were isolated and prepared as described in Methods. PP at approximately 120 mmHg was
maintained by continuous infusion with NA (10 μM and 3 μM in WKY and SHR rats, respectively). (A) and (B)
Representative tracings of vasodilator responses to submaximal ACh dose (1 μM) and to increasing concentrations of
R-568 (10 nM—30 μM) in WKY (A) and SHR (B) are shown. Each symbol represents the start of a 4-min perfusion.
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(10 nM). Maximal effect was observed at 30 μM concentration (Fig 1A) (p< 0.01 vs WKY PP
values at initial steady state). With respect to WKY, vascular activity of R-568 on MVB from
SHR was noticeably different. Indeed, as shown in Fig 1B, the vasorelaxant responses to R-568
became visible at concentrations higher than 1 μM (3–30 μM); concomitantly, the lower nM
concentrations of R-568 (10–300 nM), including the 1 μM concentration, evoked a slight but
significant increase of PP (Fig 1C; p< 0.05 vs SHR PP at initial steady state).
Thus, vascular effects of R-568 in MVB from SHR did not completely overlap with effects
observed in MVB from WKY (Fig 1C; p< 0.01 vs each respective WKY values): the high doses
of R-568 induced a comparable vasodilation in both strains whereas, in the lower range of con-
centrations, stimulation with R-568 elicited vasodilation in WKY and vasoconstriction in
SHR.
Evaluation of endothelial mediators involved in vascular effects of R-568
Nitric oxide (NO), BKCa and IKCa channels, and arachidonic acid metabolites are all involved
in the control of vessel tone. To analyze the potential contribution of these vascular mediators
on R-568-induced vascular effects, dose-response curves to R-568 were repeated in MVB pre-
treated with pharmacological inhibitors of NO synthase (L-NAME), KCa channels (CTX), and
cyclo-oxygenase (INDO) (Fig 2).
In WKY, as expected, pretreatment with L-NAME (100 μM/20 min) significantly blunted
vasorelaxation to ACh. Interestingly, L-NAME pretreatment abrogated vasodilation in
response to the lowest concentrations of R-568 (10–300 nM; Fig 2C; p< 0.05 vs CTRL curve),
but did not significantly influence vasodilation induced by the highest concentrations of R-568
(Fig 2C).
To evaluate the involvement of additional endothelial factors contributing to R-568-
induced vasodilation, MVB were subsequently treated with CTX (300 nM/20 min) and INDO
(10 μM/20 min) in combination with L-NAME. Under these conditions, residual ACh-medi-
ated vasodilation was negligible (Fig 2A). When treatment with L-NAME was combined with
CTX and INDO, a further inhibitory effect was observed on vasodilation induced by R-568 at
1 μM concentration (Fig 2A and 2C; p< 0.05 vs CTRL curve). Conversely, in the higher
micromolar range, vasodilatory effects to R-568 were not significantly reduced by the com-
bined treatment with all inhibitors together (Fig 2A and 2C).
In SHR, similar to WKY, pretreatment with L-NAME did not significantly reduce the vaso-
dilator responses obtained with the higher doses of R-568 (Fig 2D). The combined treatment
with L-NAME, CTX and INDO was unable to block the R-568-mediated vasodilation as well
(Fig 2D). Surprisingly enough, though, the small vasoconstrictor effect evoked by low doses of
R-568 in SHR was completely blocked when MVB was incubated with L-NAME, alone or in
combination with CTX and INDO (p< 0.05 vs CTRL curve) (Fig 2B and 2D).
Effect of endothelium removal and CaSR inhibition on vascular response to
R-568
The behavior of R-568 in vessels pretreated with L-NAME, CTX and INDO suggests that, for
the higher concentrations tested, vasodilation obtained with R-568 might not require endothe-
lial contribution. On the other hand, at concentrations lower than 1 μM, effects produced by
(C) Dose-response curves for R-568-induced vascular effects were obtained from MVB of WKY and SHR. Results are
the mean ± SEM of 7 (WKY) and 6 (SHR) independent experiments. Data from each curve were normalized by
defining 100% as the initial steady state PP and 0% as the maximal reduction in PP obtained in WKY treated with
1 μM ACh. p< 0.01 vs respective values.
https://doi.org/10.1371/journal.pone.0202354.g001
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R-568 were quite different in MVB from WKY (where it induced vasodilation) with respect to
SHR (where it propended to vasoconstriction).
To unquestionably ascertain the involvement of endothelium in R-568-mediated effects,
dose-response curves to R-568 were repeated in both WKY and SHR MVB before and after
endothelial removal, this last condition verified by complete lack of ACh-mediated vasodila-
tion (data not shown). In WKY rats, consistent with results obtained under L-NAME, CTX
and INDO treatment, endothelium removal inhibited R-568-mediated vasodilation in the
range of 10 nM—1 μM, but did not abrogate vasodilation at R-568 concentrations higher than
1 μM (Fig 3A; p< 0.05 vs respective CTRL curve). Likewise, in SHR rats, endothelium removal
overlapped effects observed under L-NAME pretreatment: vasodilation in response to high
concentrations of R-568 remained unchanged in the presence or in the absence of endothe-
lium (Fig 3A); once again, as described for L-NAME, vasoconstriction to lower concentrations
of R-568 was not visible in vessels without endothelium (Fig 3A; p< 0.05 vs respective CTRL
curve).
The next obligatory step was to verify the possibility that vascular effects in response to R-
568 would indeed be mediated by CaSR activation. Thus, in another set of experiments, the
Fig 2. Evaluation of endothelial mediators involved in vascular effects of R-568 in MVB from WKY and SHR rats. (A) and (B) Representative tracings of vascular
response to R-568 (10 nM—30 μM) in MVB from WKY (A) or SHR (B) pretreated with L-NAME, CTX and INDO are shown. Each symbol represents the start of a
4-min perfusion. (C) MVB isolated from 8-week old WKY (closed symbols) were stimulated with increasing concentrations of R-568 in the absence (circles) or in the
presence of L-NAME (100 μM/20 min; squares), L-NAME+CTX (300 nM/20 min; triangles), L-NAME+CTX+INDO (10 μM/20 min; diamonds). Results are the
mean ± SEM of 4 WKY independent experiments. (D) MVB isolated from 8-week old SHR (open symbols) were stimulated with increasing concentrations of R-568 in
the absence (circles) or in the presence of L-NAME (100 μM/20 min; squares), L-NAME+CTX (300 nM/20 min; triangles), L-NAME+CTX+INDO (10 μ M/20 min;
diamonds). Results are the mean ± SEM of 4 WKY and 4 SHR independent experiments. p< 0.04 and #p< 0.05 vs respective CTRL curve.
https://doi.org/10.1371/journal.pone.0202354.g002
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dose-response curves to R-568 were compared in the absence and in the presence of CaSR
blocker Calhex-231 (3 μM/20 min) in MVB from WKY and SHR rats. As expected, ACh-
mediated vasodilation was not modified by pretreatment with Calhex-231 (data not shown).
Fig 3B demonstrates that, similar to endothelium removal, inhibition of CaSR did not signifi-
cantly reduce vasodilation to high doses of R-568 in both SHR and WKY preparations On the
other hand, vasoactive effects of R-568 in the 10 nM– 1 μM concentration range were signifi-
cantly reduced under CaSR inhibition, in WKY as well as in SHR (Fig 3B). Interestingly, block-
ade of CaSR was able to abrogate both the vasodilation in MVB from WKY as well as the
vasoconstriction observed in MVB from SHR (p< 0.05 vs respective CTRL curve).
The CaSR-independent vasodilation observed in response to high doses of R-568 in our
study is consistent with results obtained with other calcimimetics: for example, the arterial
relaxation induced by both cinacalcet and calindol was not substantiallly blocked by the CaRS
inhibitor Calhex 231 in rat mesenteric vessels [16], suggesting the involvement of alternative/
additional mechanisms. Similarly, at doses exceeding 70 μM, infusion of both R-568 and its
enantiomer S-568 in rat mesenteric and renal arteries has been shown to equally increase
blood flow [22]. Given the largely stereospecific activity of calcimimetics, the Authors con-
cluded that the comparable vasodilation obtained with both R-568 and S-568 was unlikely
mediated by CaSR activation [22]. One alternative explanation for the off-target effects of calci-
mimetics is based on their chemical structure: since these molecules are phenylalkylamine
derivatives, their ability to modulate vascular relaxation and blood pressure has been mainly
ascribed to potential interaction on L-type Ca2+ channels [16, 33]. Although, at present we
cannot provide any direct evidence of an inhibitory effect of R-568 on L-type Ca2+ channels,
this may help to comprehend why, in our study, vasodilation obtained with high doses of R-
568 did not change in the absence or presence of endothelium, and was not significantly differ-
ent between SHR and WKY.
Similarly, we cannot exclude that hyperpolarization might have a role in mediating R-568
comparable vasodilator effects in SHR and WKY, in the high range of concentrations tested:
treatment with CTX, which blocks KCa channels in a nonselective fashion [37], might not affect
small conductance Ca2+-activated potassium channel (SKCa), voltage-gated potassium channel
Kv1.3, or KATP channels. Thus, especially in MVB, where hyperpolarization contributes to the
Fig 3. Effect of endothelium removal and CaSR inhibition on vascular response to R-568. (A) MVB isolated from 8-week old WKY (closed
symbols) and SHR (open symbols) were stimulated with increasing concentrations of R-568 in the presence (circles) or in the absence (squares) of
endothelium. Results shown are the mean ± SEM of 3 (WKY) and 3 (SHR) independent experiments. Data from each curve were normalized as in Fig
1. (B) MVB isolated from 8-week old WKY (closed symbols) and SHR (open symbols) were stimulated with increasing concentrations of R-568 in the
absence (circles) or after pretreatment with (diamonds) Calhex-231 (3 μM/20 min). Results are the mean ± SEM of 3 WKY and 3 SHR independent
experiments. Data from each curve were normalized as in Fig 1. p< 0.05 vs respective CTRL curve.
https://doi.org/10.1371/journal.pone.0202354.g003
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vasodilator response of several agonists [38–41], it remains possible that part of the off-target
vasodilation by R-568 might involve hyperpolarization-mediated mechanisms.
In contrast to the result obtained at high R-568 concentration, the vasodilatory effect
observed at low doses of R-568 in MVB from WKY was mediated by CaSR and dependent on
endothelial factors, in agreement with other studies demonstrating the necessary role of CaSR
and endothelium in the hypotensive effects of calcimimetics [12, 23, 42]. Conversely, in MVB
from SHR rats, the lowest concentrations of R-568 evoked a dose-dependent vasoconstrictive
effect that was both endothelium- and CaSR-mediated. This was somewhat surprising because,
if any, the impaired endothelial function in vessels from SHR was expected to reduce the vaso-
dilatory ability of R-568. Although puzzling, these findings should take into account the
genetic background of SHR that may affect endothelial production of vasoactive mediators,
resulting in abnormal/unbalanced vascular responsiveness [43]. For example, uncoupling of
eNOS is known to generate reactive oxygen species (ROS) instead of NO [44, 45]. In this case,
phosphorylation and activation of endothelial eNOS by R-568 may increase ROS levels and
elicit subsequent vasoconstriction. Preliminary immunohistochemical experiments in our
study suggest that levels of nitrotyrosine (indicating peroxinitrite production) in response to
R-568 were higher in aortas isolated from SHR when compared with samples from WKY; on
the same line, in immunofluorescence experiments, nuclear red fluorescence to dihydroethi-
dium DHE (indicative of O2- production) in response to R-568 was higher in aortic rings from
SHR with respect to aortic rings from WKY (data not shown). Thus, in vessels from SHR,
L-NAME pre-treatment or endothelial removal might mitigate the vasoconstriction elicited by
R-568-mediated stimulation of uncoupled eNOS. This hypothesis is supported by data show-
ing that treatment with the ROS scavenger Tempol was able to block the age-related develop-
ment of high blood pressure in hypertensive rats [46]. On the same line, treatment with the
antioxidant N-acetylcisteine (NAC) has been shown to effectively reduce blood pressure in
young (5 weeks of age) SHR rats [47], underscoring the role played by ROS in the early stages
of hypertension development. Alternatively, activation of CaSR might be involved in several
signaling cascades related to production of either vasoconstrictor or vasodilator factors.
Indeed, in the vascular district, CaSR activation has been associated with vasoconstriction and
signalling via mitogen-activated protein kinases [48–50]. Thus, it is plausible that in vessels
from SHR stimulation with R-568 may unmask vasoconstrictive effects not adequately coun-
terbalanced by endothelial impaired production of NO. Although our present findings are too
preliminary to exclude or confirm any hypothesis, these observations underline the specific
behavior of R-568 under hypertensive conditions.
Activation of signaling pathways by R-568 in MVB from WKY and SHR
Taken together our functional studies suggest that: 1. for concentrations higher than 1 μM, R-
568 is able to produce a vasodilatant effect that does not differ between WKY and SHR rats, it
is unlikely mediated by CaSR activation, and does not depend on NO production and/or other
endothelial factors; 2. conversely, in the lower range (10 nM -1 μM) of concentrations, both
endothelium and CaSR are required for R-568-dependent vascular activities, which translate
in vasodilation in WKY and vasoconstriction in SHR, respectively. Based on the different con-
sequences of eNOS activation under healthy and pathological conditions discussed above, we
evaluated the ability of R-568 to increase phosphorylation (activation) of eNOS in the whole
MVB homogenates. Moreover, since phosphorylation of eNOS by the upstream kinase Akt is
an important mechanism regulating activation of eNOS in response to several ligands, the
phosphorylation levels of eNOS and Akt were concomitantly measured in both WKY and
SHR preparations. As shown in Fig 4 levels of phospho-eNOS and phospho-Akt increased
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proportionally to concentrations of R-568 administered, with a quantifiable effect on Akt start-
ing at 100 nM (p< 0.05 vs respective unstimulated conditions). Thus, in normotensive WKY,
R-568-mediated vasodilation was associated with an Akt-associated activation of eNOS. These
findings corroborate literature data demonstrating that stimulation of CaSR induces eNOS
activation and NO release, which in turn produces relaxation by regulating extracellular Ca2+
in mesenteric arteries from mice [19], and involves the heteromeric transient receptors
TRPV4-TRPC1 channels in mesenteric arteries from rabbits [14].
Conversely, in preparations from SHR, no significant increase in phosphorylated levels of
Akt and eNOS was detected in MVB stimulated with the same R-568 concentrations (Fig 4),
suggesting the impairment of Akt/eNOS signaling activation in response to R-568. Therefore,
differences in molecular mechanisms activated by R-568 in whole vessels from WKY and SHR
support the diverging functional effects observed in these two strains.
CaSR expression in WKY- and SHR-vSMCs
Endothelial cells constitute only a very small fraction of the total protein in a whole vessel.
This, together with the concept that the phenotypic modulation of VSMCs is known to play a
pivotal role in hypertension-induced vascular changes [51], advocate for our subsequent
Fig 4. Evaluation of signaling pathways activated by R-568 in MVB from WKY and SHR. MVB homogenates from experiments described in
Fig 1 were subjected to immunoblotting for total and phosphorylated forms of Akt (phospho-AktSer473), and eNOS (phospho-eNOSSer1177). Total
β-actin levels were used as loading control. A representative set of immunoblots is shown for experiments that were repeated independently 3
times. Each bar represents the mean ± SEM of densitometric analysis for phosphorylated proteins normalized to their respective total forms.
p< 0.05 vs respective basal.
https://doi.org/10.1371/journal.pone.0202354.g004
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studies investigating the role of vSMCs on R-568-mediated effects. The presence of CaSR on
vSMCs is still controversial [49, 50, 52, 53], with some studies reporting the expression of
CaSR in human and animal models [5, 6, 48, 49] while some others have failed to detect the
cognate CaSR in vSMCs [52]. Furthermore, the discovery and cloning of a novel human family
of C GPCR, with a significant homology to the human CaSR, suggest the presence of a distinct
calcium sensing receptor termed GPRC6A and its possible activation by high concentrations
of extracellular calcium and calcimimetics [54, 55].
Here, following the isolation of vSMCs from the thoracic aorta of WKY and SHR rats, we
first confirmed their phenotype by evaluating the contractile marker α-SMA that resulted
90% for both vSMCs strains (Fig 5C). Then, we compared the morphological characteristics of
cell cultures from WKY and SHR. As shown in Fig 5A, the WKY-vSMCs showed a ‘‘hill and
valley” morphology typically observed in cultured vSMCs [56]. SHR-vSMCs, on the contrary,
showed an atypical morphology, suggestive of altered mechanisms controlling contact
Fig 5. CaSR expression in WKY- and SHR-vSMVCs. (A) Representative morphometric aspect of confluent vSMC cultures from normotensive rats (WKY) and
spontaneously hypertensive rats (SHR) (magnification x 10; scale bar: 300 μM). The cells were plated and morphologically examined three different times in the
same experimental conditions. (B) Representative pattern of electrophoretic bands (170–100, 70–55 and 40–25 kDa) that results from immunoblotting analysis of
CaSR expression in WKY- and SHR-vSMCs lysates and its negative (NC, HEK293 empty vector transfected control cell lysate) and positive (PC, HEK293 CaSR
transiently transfected cell lysate) controls. (C) Representative images of α-SMA flow cytometry analysis in WKY-and SHR-vSMCs and secondary antibody alone
(control).
https://doi.org/10.1371/journal.pone.0202354.g005
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inhibition. To ascertain if changes in vSMCs morphology might also reflect a differential
expression of CaSR protein between WKY- and SHR-vSMCs, a western blot analysis was per-
formed in cell lysates under reducing conditions. As shown in Fig 5B, and consistent with our
and other previous reports on HUVECs [17, 57] we observed a pattern of electrophoretic
bands (170–100, 70–55 and 40–25 kDa) indicative of CaSR protein. The different molecular
weight is depending upon the extent of proteins glycosylation and the presence of its mono-
meric or multimeric form [58, 59].
On this respect, it is important to specify that the functional CaSR resides on the cell surface
in the dimeric form, while the intracellular pool of CaSR has been considered a rapidly mobi-
lizable “storage form” [60, 61] with a potential role in the modulation of intracellular activities
triggered by changes in endoplasmic reticulum Ca2+ and/or glutathione [61].
Interestingly, this pattern of bands reveal the mature and biologically active dimeric form of
the receptor (170 kDa) in the WKY-vSMCs, whereas in the SHR-vSMCs the monomeric CaSR
protein (70 kDa) resulted the most expressed (Fig 5B).
Effect of R-568 on Akt activation and NO production in vSMCs from WKY
and SHR rats
The possibility that, besides endothelium, CaSR expressed on vSMCs may also participate to
vascular activities of R-568 was then evaluated. As shown in Fig 6A, after two minutes of stim-
ulation, R-568 (1 μM) induced a significant increase in Akt phosphorylation levels (p< 0.02 vs
respective unstimulated conditions) on WKY-vSMCs while no significant activation of Akt
signaling was found on SHR-vSMCs. Pre-incubation with CaSR inhibitor Calhex (1 μM)
completely reverted the R-568-dependent phosphorylation of Akt in WKY-vSMCs (p< 0.05
vs respective R-568 alone).
Similar to endothelial cells, activation of Akt in vSMCs has been linked to activation of
eNOS, whose expression has previously been unequivocally documented in vSMCs from mice
[62] as well as from humans, under both basal and pathological conditions [63, 64]. Thus,
NOS activity in response to R-568 was evaluated in WKY- and SHR-vSMCs by a conventional
method indirectly measuring the conversion of the substrate L-[3H]-arginine into L-[3H]-cit-
rulline [28, 31]. As shown in Fig 6B, vSMCs stimulation with R-568 (1 μM) was associated to a
significant production of NO in WKY cells (p< 0.02 vs respective unstimulated conditions)
that reverted to baseline levels when cells were concomitantly treated with the CaSR inhibitor
Calhex 231 (1 μM) (p< 0.01 vs respective R-568 alone).
Similar to Akt phosphorylation levels, no significant increase in NO production was mea-
sured in vSMCs from SHR. Collectively, these findings support the hypothesis that the absence
of the CaSR active dimeric form in vSMCs from SHR rats may contribute to explain the
impaired vasorelaxant effect observed in response to R-568 in MVB from SHR, with respect to
WKY [33].
Conclusions
Taken together, these findings highlight new mechanisms of action of calcimimetics in modu-
lating vascular tone, both in normal and pathological conditions such as hypertension. In iso-
lated vessels from hypertensive compared to normotensive rats, the calcimimetic R-568 exerts
different dose-dependent vasodilatory effects. Particularly, at the lowest R-568 concentrations
used, its effect in isolated vessels results opposite: vasodilatory in WKY and vasoconstrictor in
SHR. In both cases dependent on the CaSR and the endothelium itself, while the involvement
of vSMCs in the R-568 CaSR-dependent vasodilatation might be assumed only for WKY rats.
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Fig 6. Effect of R-568 on Akt activation and NO production in vSMCs from WKY and SHR rats. (A) vSMCs stimulated with 1μM of R568 (R)
at different times (30 seconds, 1 minute, 2 minutes) in the presence or absence of Calhex 231 (C, 1 μM) were subjected to immunoblotting for
total and phosphorylated forms of Akt (phospho-AktSer473). Total β-actin levels were used as loading control. A representative set of immunoblots
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Although further studies are necessary to thoroughly understand these effects, our study
suggest that calcimimetics might be useful to regulate vascular tone and this could represent
the beginning of a new therapeutic approach.
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